Editorial: Why JAACAP Published an "Inconclusive" Trial: Optimize, Optimize, Optimize Psychostimulant Treatment

Area of Science:

• Child and Adolescent Psychiatry
• Neurodevelopmental Disorders
• Pharmacological Interventions

Background:

• Investigated adjunctive risperidone, valproate, or placebo for aggressive behaviors in children (6-12 years) with ADHD and comorbid ODD/CD.
• Included participants with persistent aggression despite optimized psychostimulant treatment and behavioral therapy.

Discussion:

• An unexpectedly high remission rate (63.6%) during the optimization phase significantly reduced the number of participants eligible for randomization.
• The study highlights the impact of optimization phases on subsequent randomized controlled trial (RCT) design and participant recruitment.

Key Insights:

• The optimization phase demonstrated substantial efficacy of behavioral treatment and optimized psychostimulants in reducing aggression.
• The limited sample size in the randomized phase (n=40) impacted the trial's statistical power to compare adjunctive treatments.

Outlook:

• The findings emphasize the importance of robust optimization strategies in managing pediatric aggression associated with ADHD and ODD/CD.
• Recommends greater transparency in reporting optimization phase outcomes to inform future clinical trial methodologies and interpretations.